RADX vs NVS

For growth investors, Radiopharm Theranostics Limited (RADX) is the stronger pick with 1114% revenue growth year-over-year, versus 6.

0% for Novartis AG (NVS). Novartis AG (NVS) offers the better valuation at 20. 2x trailing P/E (16. 6x forward), making it the more compelling value choice. Analysts rate Novartis AG (NVS) a "Hold" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +94.

4%, compared to -76. 5% for Radiopharm Theranostics Limited (RADX). Over 10 years, the gap is even starker: NVS returned +178. 5% versus RADX's -76. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Novartis AG (NVS) is the lower-risk stock at 0.

42β versus Radiopharm Theranostics Limited's 0. 88β — meaning RADX is approximately 107% more volatile than NVS relative to the S&P 500.

By revenue growth (latest reported year), Radiopharm Theranostics Limited (RADX) is pulling ahead at 1114% versus 6.

0% for Novartis AG (NVS). On earnings-per-share growth, the picture is similar: Radiopharm Theranostics Limited grew EPS 85. 3% year-over-year, compared to 22. 5% for Novartis AG. Over a 3-year CAGR, RADX leads at 643. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novartis AG (NVS) is the more profitable company, earning 25.

6% net margin versus -1055. 3% for Radiopharm Theranostics Limited — meaning it keeps 25. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus -1050. 6% for RADX. At the gross margin level — before operating expenses — NVS leads at 75. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, NVS (2.

8% yield) pays a dividend. RADX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 2. 8% yield, +178. 5% 10Y return). Both have compounded well over 10 years (NVS: +178. 5%, RADX: -76. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RADX is a small-cap high-growth stock; NVS is a large-cap quality compounder stock. NVS pays a dividend while RADX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.